相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Managing Cutaneous Side Effects From Targeted Molecular Inhibitors for Melanoma and Nonmelanoma Skin Cancer
Nikki Tang et al.
DERMATOLOGIC SURGERY (2016)
Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib
Georgina V. Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma
Paola Queirolo et al.
CANCER TREATMENT REVIEWS (2015)
Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit
Rashmi R. Shah et al.
DRUG SAFETY (2015)
Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma
Dirk Schadendorf et al.
EUROPEAN JOURNAL OF CANCER (2015)
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Dirk Schadendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Georgina V. Long et al.
LANCET (2015)
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma
Sarah J. Welsh et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2015)
Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial
A. M. Menzies et al.
ANNALS OF ONCOLOGY (2015)
Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib
Dafina Draganova et al.
JOURNAL OF OPHTHALMIC INFLAMMATION AND INFECTION (2015)
Current Systemic Therapies for Melanoma
Darren M. Palathinkal et al.
DERMATOLOGIC SURGERY (2014)
Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAFV600-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor
Douglas B. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma
Clara I. Lee et al.
MELANOMA RESEARCH (2014)
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
James Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Cutaneous toxicities of RAF inhibitors
Rachael Anforth et al.
LANCET ONCOLOGY (2013)
Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma
R. M. Anforth et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma
Georgina V. Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Final Version of 2009 AJCC Melanoma Staging and Classification
Charles M. Balch et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
分享论文
